SOPHiA GENETICS SA (SOPH) 주식 분석

회사 개요

SOPHiA GENETICS SA operates as a cloud-native software technology enterprise within the healthcare sector, specifically focusing on Health Information Services. The company provides the SOPHiA DDM platform, a sophisticated cloud-native solution designed for analyzing complex data sets and generating actionable insights from multimodal data sources and various diagnostic modalities. This entity maintains a substantial operational scale with a total market capitalization of $348.31 million and an annual revenue of $77.27 million based on trailing twelve-month figures. The workforce supporting these technological operations consists of 415 employees, indicating a mid-sized organizational structure typical for specialized health information service providers. The valuation metrics reveal a company with a market cap significantly larger than its current trailing revenue base, suggesting the market prices the firm based on future growth potential and intellectual property value rather than current earnings profitability.

재무 건전성

The financial performance of SOPHiA GENETICS SA demonstrates a revenue stream of $77.27 million for the trailing twelve months, yet this is contrasted by a net income loss of $-78,999,000 and an EBITDA of $-69,168,000. The substantial gap between the positive revenue and negative net income highlights an aggressive cost structure where operating expenses, including research and development, heavily outweigh current earnings, a common trait in high-growth technology firms. The company's free cash flow stands at $-16,462,000, indicating that capital expenditures and working capital requirements currently exceed cash generated from operations, which limits immediate financial flexibility for external expansion. Margin analysis reveals a gross margin of 67.4%, suggesting high pricing power or low cost of goods sold relative to revenue, while the operating margin of -85.4% and profit margin of -102.2% reflect significant overhead costs relative to sales. Liquidity and solvency are characterized by a cash balance of $70.29 million against a debt obligation of $63.02 million, resulting in a debt-to-equity ratio of 133.67. While the company holds more cash than debt, the high debt-to-equity ratio indicates a leveraged balance sheet relative to shareholder equity, though the positive cash buffer provides a safety margin against short-term obligations. Short-term liquidity is supported by a current ratio of 1.96, which suggests the firm possesses sufficient current assets to cover its current liabilities nearly twice over. Return metrics show a return on equity of -110.0% and a return on assets of -27.9%, revealing that management is currently generating negative returns on both shareholder capital and the asset base utilized to generate revenue.

밸류에이션 평가

Valuation multiples for SOPHiA GENETICS SA present a challenging picture due to the lack of profitability, with a trailing P/E ratio listed as N/A and a forward P/E of -8.68. The absence of a positive trailing P/E combined with a negative forward P/E implies that the market is pricing in an expectation of future earnings recovery or that the current valuation relies entirely on non-earnings metrics like revenue growth. The price-to-book ratio is 7.06, indicating that the stock trades at a significant premium to its book value, which reflects the market's high valuation of the company's intangible assets and proprietary software platforms. Alternative valuation metrics such as the price-to-sales ratio of 4.51 and an EV/EBITDA of -4.93 suggest that investors are willing to pay a high multiple per dollar of sales despite current losses. The stock's price volatility is defined by a 52-week high of $5.70 and a 52-week low of $2.58, meaning the current trading price sits at a level that fluctuates significantly within this established range. The beta value of 1.04 indicates that the stock's price volatility generally moves in line with the broader market, suggesting it does not offer significant diversification benefits through reduced volatility but also does not amplify market swings excessively.

Growth & Income

The revenue growth year-over-year stands at 22.4%, demonstrating a robust expansion in the top line, while earnings growth is listed as N/A due to the company's current net loss position. The disparity between strong revenue growth and the absence of positive earnings growth implies that the company is prioritizing market share acquisition and platform development over immediate profitability. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, confirming that all generated cash is reinvested into the business operations and research initiatives rather than distributed to shareholders. The overall growth and income profile is characterized by high revenue expansion coupled with a complete reinvestment of earnings to fund future growth, with no current income generation from dividends.